Merck KGaA (FRA:MRK) has been assigned a €115.00 ($135.29) price objective by analysts at Kepler Capital Markets in a research note issued to investors on Monday. The brokerage presently has a “buy” rating on the healthcare company’s stock. Kepler Capital Markets’ target price suggests a potential upside of 23.15% from the stock’s current price.

Other research analysts have also issued research reports about the stock. S&P Global set a €110.00 ($129.41) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research note on Thursday, August 3rd. equinet AG set a €112.00 ($131.76) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, August 31st. BNP Paribas set a €116.00 ($136.47) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Wednesday, September 6th. Warburg Research set a €115.00 ($135.29) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Wednesday, September 6th. Finally, Bank of America Corporation set a €110.00 ($129.41) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Wednesday, September 6th. Thirteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Merck KGaA has a consensus rating of “Hold” and a consensus target price of €109.17 ($128.44).

Shares of Merck KGaA (MRK) opened at €93.48 ($109.98) on Monday. Merck KGaA has a 52-week low of €89.00 ($104.71) and a 52-week high of €115.00 ($135.29).

TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/kepler-capital-markets-analysts-give-merck-kgaa-mrk-a-115-00-price-target/1682088.html.

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with Analyst Ratings Network's FREE daily email newsletter.